EGFR receptor double mutation, L858R)T790M. Several of these irreversible
inhibitors, namely HKI-272, EKB-569, BIBW2992, and PF00299804, are currently undergoing clinical testing;
however, none of them have
https://www.justice.gov/epstein/files/DataSet%209/EFTA01085311.pdf